Results 191 to 200 of about 29,353 (245)

Cholinergic neuronal activity promotes diffuse midline glioma growth through muscarinic signaling. [PDF]

Cell
Drexler R, Drinnenberg A, Gavish A, Yalçin B, Shamardani K, Rogers AE, Mancusi R, Trivedi V, Taylor KR, Kim YS, Woo PJ, Soni N, Su M, Ravel A, Tatlock E, Midler A, Wu SH, Ramakrishnan C, Chen R, Ayala-Sarmiento AE, Fernandez Pacheco DR, Siverts L, Daigle TL, Tasic B, Zeng H, Breunig JJ, Deisseroth K, Monje M.   +27 more
europepmc   +1 more source

Neuroimmune circuits in respiratory pathophysiology: decoding molecular crosstalk for precision therapeutic targeting. [PDF]

Ann Med
Chen Q, Jia N, Liu J, Xu C, Shen Z, Shi S, Wang F, Wang Z.   +7 more
europepmc   +1 more source

Cholinergic heterogeneity facilitates synchronization and information flow in a whole-brain model

Dalla Porta L, Fousek J, Destexhe A, Sanchez-Vives MV.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

M1 muscarinic acetylcholine receptor‐mediated inhibition of GABA release from striatal medium spiny neurons onto cholinergic interneurons

European Journal of Neuroscience, 2020
Acetylcholine (ACh) modulates neurotransmitter release in the central nervous system. Although GABAergic transmission onto the striatal cholinergic interneurons (ChIN) is modulated by dopamine receptors, cholinergic modulation of the same synapse is ...
Etsuko Suzuki, T. Momiyama
semanticscholar   +1 more source

Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders

European Journal of Neurology, 2007
The Lambert–Eaton myasthenic syndrome (LEMS), often associated with small‐cell lung carcinoma (SCLC), is a disorder of acetylcholine (ACh) release from motor nerve terminals. In most patients, it is caused by autoantibodies against the P/Q‐type voltage‐gated calcium channels (VGCC) that trigger ACh release. However, these antibodies are not detected in
M, Takamori, M, Motomura, T, Fukudome, H, Yoshikawa   +3 more
openaire   +2 more sources

Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice

Nature Neuroscience, 2002
Blockade of cholinergic neurotransmission by muscarinic receptor antagonists produces profound deficits in attention and memory. However, the antagonists used in previous studies bind to more than one of the five muscarinic receptor subtypes. Here we examined memory in mice with a null mutation of the gene coding the M1 receptor, the most densely ...
Stephan G, Anagnostaras, Geoffrey G, Murphy, Susan E, Hamilton, Scott L, Mitchell, Nancy P, Rahnama, Neil M, Nathanson, Alcino J, Silva   +6 more
openaire   +2 more sources

Targeting the M1 muscarinic acetylcholine receptor in neurodegeneration

2023
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, and to date, no disease-modifying treatments exist. The M1 muscarinic acetylcholine receptor (mAChR) is an established therapeutic target for the symptomatic treatment of AD, and drugs activating the M1 mAChR have been shown to improve cognitive decline and behavioural symptoms in ...
openaire   +2 more sources

Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.

ACS Chemical Neuroscience, 2018
Preclinical and clinical data suggest that muscarinic acetylcholine receptor activation may be therapeutically beneficial for the treatment of schizophrenia and Alzheimer's diseases.
C. Thorn, Joshua Moon, Clinton A Bourbonais, J. Harms, J. Edgerton, Eda Stark, Stefanus J. Steyn, Christopher R Butter, J. Lazzaro, Rebecca E O'connor, M. Popiolek   +10 more
semanticscholar   +1 more source